{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:08:51Z","timestamp":1786993731072,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.lungcan.2023.107316","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T13:49:22Z","timestamp":1690379362000},"page":"107316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, PD-L1+\u226550% of tumor cells in France: A modeling study"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8993-7569","authenticated-orcid":false,"given":"Ingrid","family":"Plessala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Cawston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roula","family":"Ajjouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katell","family":"Le Lay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Jean","family":"Souquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.107316_b0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jtho.2020.09.012","article-title":"Lung Cancer in France","volume":"16","author":"Pujol","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107316_b0010","first-page":"844","article-title":"Epidemiology of lung cancer in France and in the world","volume":"70","author":"Brosseau","year":"2020","journal-title":"Rev. Prat."},{"key":"10.1016\/j.lungcan.2023.107316_b0015","first-page":"100492","article-title":"Lung cancer trends and tumor characteristic changes over 20 years (2000\u20132020): Results of three French consecutive nationwide prospective cohorts\u2019 studies, Lancet Reg","volume":"22","author":"Debieuvre","year":"2022","journal-title":"Health Eur."},{"key":"10.1016\/j.lungcan.2023.107316_b0020","unstructured":"Institut National du Cancer, Le cancer du poumon - Les cancers les plus fr\u00e9quents, (2022). https:\/\/www.e-cancer.fr\/Professionnels-de-sante\/Les-chiffres-du-cancer-en-France\/Epidemiologie-des-cancers\/Les-cancers-les-plus-frequents\/Cancer-du-poumon (accessed March 9, 2022)."},{"key":"10.1016\/j.lungcan.2023.107316_b0025","doi-asserted-by":"crossref","unstructured":"P.E. Postmus, K.M. Kerr, M. Oudkerk, S. Senan, D.A. Waller, J. Vansteenkiste, C. Escriu, S. Peters, Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol. 28 (2017) iv1\u2013iv21. doi: 10.1093\/annonc\/mdx222.","DOI":"10.1093\/annonc\/mdx222"},{"key":"10.1016\/j.lungcan.2023.107316_b0030","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"JCO."},{"key":"10.1016\/j.lungcan.2023.107316_b0035","unstructured":"European Medicines Agency, Tecentriq (atezolizumab) - Summary of Product Characteristics, 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecentriq-epar-product-information_en.pdf."},{"key":"10.1016\/j.lungcan.2023.107316_b0040","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2023.107316_b0045","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS), Avis sur les m\u00e9dicaments. TECENTRIQ 840 mg et 1200 mg., 2022. https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-19903_TECENTRIQ_PIC_EI_AvisDef_CT19903.pdf (accessed February 1, 2023)."},{"key":"10.1016\/j.lungcan.2023.107316_b0050","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s13555-020-00446-z","article-title":"Cost\u2013utility analysis of nivolumab in adjuvant treatment of melanoma in France","volume":"10","author":"Bregman","year":"2020","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"10.1016\/j.lungcan.2023.107316_b0055","doi-asserted-by":"crossref","first-page":"S464","DOI":"10.1016\/j.jval.2019.09.345","article-title":"PCN149 Cost-effectiveness analysis of dabrafenib+trametinib versus watchful waiting in the adjuvant treatment of patients with resected BRAF V600 positive stage III melanoma: a French perspective","volume":"22","author":"Cariou","year":"2019","journal-title":"Value Health."},{"key":"10.1016\/j.lungcan.2023.107316_b0060","series-title":"NICE DSU Technical support document 19: Partitioned survival analysis for decision modelling in health care: a critical review","first-page":"72","author":"Woods","year":"2017"},{"key":"10.1016\/j.lungcan.2023.107316_b0065","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","article-title":"Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?","volume":"23","author":"Woods","year":"2020","journal-title":"Value Health."},{"key":"10.1016\/j.lungcan.2023.107316_b0070","unstructured":"Haute Autorit\u00e9 de la Sant\u00e9 (HAS), Choix m\u00e9thodologiques pour l\u2019\u00e9valuation \u00e9conomique \u00e0 la HAS, (2020) 118."},{"key":"10.1016\/j.lungcan.2023.107316_b0075","unstructured":"R\u00e9f\u00e9rentiels Auverge Rh\u00f4ne-Alpes en Oncologie Thoracique, Formes m\u00e9tastatiques \u2013 stade IV \u2013 AURA, (n.d.). http:\/\/referentiels-aristot.com\/129-cancer-bronchique-non-petites-cellules\/134-modalites-therapeutiques\/138-formes-metastatiques-stade-iv\/ (accessed March 15, 2022)."},{"key":"10.1016\/j.lungcan.2023.107316_b0080","unstructured":"R\u00e9f\u00e9rentiels Auvergne Rh\u00f4ne-Alpes en Oncologie Thoracique, Stade I et II cliniques (bilan pr\u00e9-th\u00e9rapeutique), patient op\u00e9rable \u2013 AURA, (2021). http:\/\/referentiels-aristot.com\/129-cancer-bronchique-non-petites-cellules\/134-modalites-therapeutiques\/135-stade-i-et-ii-cliniques-bilan-pretherapeutique-patient-operable\/ (accessed December 22, 2021)."},{"key":"10.1016\/j.lungcan.2023.107316_b0085","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2023.107316_b0090","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.annonc.2022.02.090","article-title":"80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study","volume":"33","author":"Felip","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107316_b0095","unstructured":"E. Felip, Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study, (2022). https:\/\/medically.roche.com\/global\/en\/medical-material.58544518-b20e-46e7-9229-f5c45efbedcf.qr.html?cid=slpsxx2204onlcelcc2022 (accessed July 7, 2023)."},{"key":"10.1016\/j.lungcan.2023.107316_b0100","unstructured":"A. Brunelli, IMpower010: exploratory analysis of outcomes by surgery type in patients with PD-L1 TC \u226550% stage II-IIIA NSCLC - ESTS-2023-presentation-brunelli-impower010-exploratory-analysis-of-outcomes-by-surgery.pdf, (2023). https:\/\/medically.roche.com\/global\/en\/medical-material.7b0ba002-53e0-4691-9b22-afd14f77da40.qr.html?cid=slpsxx2306onlcests2023 (accessed July 7, 2023)."},{"key":"10.1016\/j.lungcan.2023.107316_b0105","unstructured":"N.R. Latimer, NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside Clinical Trials\u2014 Extrapolation with Patient-Level Data, 2011. http:\/\/journals.sagepub.com\/doi\/10.1177\/0272989X12472398 (accessed October 26, 2022)."},{"key":"10.1016\/j.lungcan.2023.107316_b0110","article-title":"Comparison of radiotherapy and chemoradiotherapy for locoregional recurrence of non-small cell lung cancer developing after surgert","volume":"441\u2013448","author":"Nakamichi","year":"2017","journal-title":"Clin. Lung Cancer."},{"key":"10.1016\/j.lungcan.2023.107316_b0115","article-title":"Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinoma","volume":"70\u201376","author":"Kruser","year":"2014","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107316_b0120","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107316_b0125","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival Aanalyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107316_b0130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2016.11.002","article-title":"Impact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: A nationally representative cohort study","volume":"102","author":"Wong","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107316_b0135","unstructured":"National Institutes of Health, A study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer who have failed platinum-containing therapy (OAK), (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02008227."},{"key":"10.1016\/j.lungcan.2023.107316_b0140","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/JTO.0b013e318299243b","article-title":"Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting","volume":"8","author":"Chouaid","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107316_b0145","unstructured":"Haute Autorit\u00e9 de la Sant\u00e9 (HAS), Avis \u00e9conomique. Tecentriq (atezolizumab) en association au bevacizumab, au carboplatine et au paclitaxel, dans le Cancer bronchique non \u00e0 petites cellules non \u00e9pidermo\u00efde (en 1\u00e8re ligne), 2019. https:\/\/www.has-sante.fr\/jcms\/p_3113584\/fr\/tecentriq-cancer-bronchique-non-a-petites-cellules-1ere-ligne-atezolizumab."},{"key":"10.1016\/j.lungcan.2023.107316_b0150","unstructured":"Haute Autorit\u00e9 de la Sant\u00e9 (HAS), Avis \u00e9conomique. Libtayo (cemiplimab), 2021. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-03\/libtayo_pic_ins_avisdef_ct18038.pdf (accessed March 15, 2022)."},{"key":"10.1016\/j.lungcan.2023.107316_b0155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1477-7525-6-84","article-title":"Health state utilities for non small cell lung cancer","volume":"6","author":"Nafees","year":"2008","journal-title":"Health Qual. Life Outcomes."},{"key":"10.1016\/j.lungcan.2023.107316_b0160","unstructured":"INSEE, Indice des prix \u00e0 la consommation harmonis\u00e9 - Base 2015 - Ensemble des m\u00e9nages - France - Nomenclature Coicop\u00a0: 06.3.0.0 - Services hospitaliers, (n.d.). https:\/\/www.insee.fr\/fr\/statistiques\/serie\/001763338 (accessed November 18, 2022)."},{"key":"10.1016\/j.lungcan.2023.107316_b0165","unstructured":"INSEE, Indice des prix \u00e0 la consommation harmonis\u00e9 - Base 2015 - Ensemble des m\u00e9nages - France - Nomenclature Coicop\u00a0: 06.2.1 - Services m\u00e9dicaux, (n.d.). https:\/\/www.insee.fr\/fr\/statistiques\/serie\/001763071 (accessed December 23, 2022)."},{"key":"10.1016\/j.lungcan.2023.107316_b0170","unstructured":"Assurance Maladie, BdMIT, BdM_IT\u00a0: Recherche par code, (n.d.). http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/index.php?p_site=AMELI (accessed January 4, 2022)."},{"key":"10.1016\/j.lungcan.2023.107316_b0175","unstructured":"ATIH, Stats ATIH, (n.d.). https:\/\/www.scansante.fr\/ (accessed July 27, 2022)."},{"key":"10.1016\/j.lungcan.2023.107316_b0180","unstructured":"Haute Autorit\u00e9 de la Sant\u00e9 (HAS), Avis \u00e9conomique. OPDIVO (nivolumab) dans le cancer de l\u2019\u0153sophage ou l\u2019ad\u00e9nocarcinome de la jonction \u0153so-gastrique, 2022. https:\/\/www.has-sante.fr\/jcms\/p_3324307\/fr\/opdivo-nivolumab-cancer-oesophage-ou-jonction-oeso-gastrique (accessed January 18, 2023)."},{"key":"10.1016\/j.lungcan.2023.107316_b0185","unstructured":"Haute Autorit\u00e9 de la Sant\u00e9 (HAS), Avis \u00e9conomique. KEYTRUDA (pembrolizumab) dans le cancer colorectal m\u00e9tastatique, 2021. https:\/\/www.has-sante.fr\/jcms\/p_3272286\/fr\/keytruda-pembrolizumab-cancer-colorectal-metastatique (accessed November 18, 2022)."},{"key":"10.1016\/j.lungcan.2023.107316_b0190","unstructured":"Haute Autorit\u00e9 de la Sant\u00e9 (HAS), Avis \u00e9conomique. KADCYLA (trastuzumab emtansine) dans le traitement adjuvant du cancer du sein pr\u00e9coce HER2+, 2020. https:\/\/www.has-sante.fr\/jcms\/p_3188463\/fr\/kadcyla#analyseEco."},{"key":"10.1016\/j.lungcan.2023.107316_b0195","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1016\/j.jtho.2022.07.429","article-title":"EP04.01-017 Cost-Effectiveness of Atezolizumab for Adjuvant Treatment of Patients with Stage II-IIIA PD-L1+ Non-small Cell Lung Cancer","volume":"17","author":"Das","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107316_b0200","article-title":"Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107316_b0205","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/13696998.2023.2188844","article-title":"Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1","volume":"26","author":"Escudero-Vilaplana","year":"2023","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.lungcan.2023.107316_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.03.007","article-title":"Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing \u226550% PD-L1: A United Kingdom health care perspective","volume":"179","author":"Yip","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107316_b0215","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/oncolo\/oyac021","article-title":"Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer","volume":"27","author":"Lemmon","year":"2022","journal-title":"Oncologist."},{"key":"10.1016\/j.lungcan.2023.107316_b0220","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1002\/cam4.4798","article-title":"Cost-effectiveness of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer in China","volume":"11","author":"Zhou","year":"2022","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2023.107316_b0225","unstructured":"ABECMA (idecabtagene vicleucel) - My\u00e9lome multiple, Haute Autorit\u00e9 de Sant\u00e9. (n.d.). https:\/\/www.has-sante.fr\/jcms\/p_3303102\/fr\/abecma-idecabtagene-vicleucel-myelome-multiple (accessed November 18, 2022)."},{"key":"10.1016\/j.lungcan.2023.107316_b0230","unstructured":"TECENTRIQ (at\u00e9zolizumab) - Carcinome h\u00e9patocellulaire (CHC), Haute Autorit\u00e9 de Sant\u00e9. (n.d.). https:\/\/www.has-sante.fr\/jcms\/p_3240699\/fr\/tecentriq-atezolizumab-carcinome-hepatocellulaire-chc (accessed November 18, 2022)."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:04:48Z","timestamp":1759237488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223008541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":46,"alternative-id":["S0169500223008541"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107316","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, PD-L1+\u226550% of tumor cells in France: A modeling study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107316"}}